MA50093A - Composé pentacyclique - Google Patents

Composé pentacyclique

Info

Publication number
MA50093A
MA50093A MA050093A MA50093A MA50093A MA 50093 A MA50093 A MA 50093A MA 050093 A MA050093 A MA 050093A MA 50093 A MA50093 A MA 50093A MA 50093 A MA50093 A MA 50093A
Authority
MA
Morocco
Prior art keywords
pentacyclic compound
pentacyclic
compound
Prior art date
Application number
MA050093A
Other languages
English (en)
Other versions
MA50093B1 (fr
Inventor
Koji Hagiwara
Tamaki HOSHIKAWA
Yoshihisa Kobayashi
Yoshihiko Norimine
Yoshiaki Ohashi
Nobuhiro Sato
Yu Yoshida
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA50093A publication Critical patent/MA50093A/fr
Publication of MA50093B1 publication Critical patent/MA50093B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA50093A 2017-09-07 2018-09-05 Composé pentacyclique MA50093B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017172169 2017-09-07
PCT/JP2018/032797 WO2019049869A1 (fr) 2017-09-07 2018-09-05 Composé pentacyclique

Publications (2)

Publication Number Publication Date
MA50093A true MA50093A (fr) 2021-05-05
MA50093B1 MA50093B1 (fr) 2022-05-31

Family

ID=65517037

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50093A MA50093B1 (fr) 2017-09-07 2018-09-05 Composé pentacyclique

Country Status (33)

Country Link
US (1) US10239889B1 (fr)
EP (1) EP3680243B1 (fr)
JP (1) JP6557441B1 (fr)
KR (1) KR102307738B1 (fr)
CN (1) CN111051316B (fr)
AR (1) AR112788A1 (fr)
AU (1) AU2018330578B2 (fr)
BR (1) BR112020003197A2 (fr)
CA (1) CA3072740A1 (fr)
CL (1) CL2020000376A1 (fr)
CO (1) CO2020001471A2 (fr)
CY (1) CY1125355T1 (fr)
DK (1) DK3680243T3 (fr)
ES (1) ES2903172T3 (fr)
HR (1) HRP20220019T1 (fr)
HU (1) HUE056791T2 (fr)
IL (1) IL272652B (fr)
JO (1) JOP20200030A1 (fr)
LT (1) LT3680243T (fr)
MA (1) MA50093B1 (fr)
MD (1) MD3680243T2 (fr)
MX (1) MX2020001786A (fr)
PH (1) PH12020500341A1 (fr)
PL (1) PL3680243T3 (fr)
PT (1) PT3680243T (fr)
RS (1) RS62796B1 (fr)
RU (1) RU2754557C1 (fr)
SG (1) SG11202001240XA (fr)
SI (1) SI3680243T1 (fr)
TW (1) TWI707859B (fr)
UA (1) UA125940C2 (fr)
WO (1) WO2019049869A1 (fr)
ZA (1) ZA202000970B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
JP2020533317A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド 特異的ａｋｔ３活性化剤およびその使用
BR112021015975A2 (pt) * 2019-03-05 2021-10-05 Eisai R&D Management Co., Ltd. Composto heterocíclico pentacíclico
CA3129764A1 (fr) 2019-03-05 2020-09-10 Eisai R&D Management Co., Ltd. Sel de compose pentacyclique et cristaux de celui-ci
EP4069369A4 (fr) * 2019-12-06 2024-02-14 Schrödinger, Inc. Composés cycliques et leurs procédés d'utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187306A (en) * 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
DD258234A1 (de) * 1987-03-05 1988-07-13 Univ Leipzig Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine
RU2117670C1 (ru) * 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (fr) * 1990-02-08 1993-01-01 Pfizer
KR100203456B1 (ko) 1995-06-20 1999-06-15 한승수 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제
FR2779652B1 (fr) * 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
CA2584757C (fr) * 2004-10-20 2012-07-03 F. Hoffmann-La Roche Ag Derives de benzodiazepine a substitution halogene
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
US8192080B2 (en) 2007-01-23 2012-06-05 Tsi Technologies Llc Microwire-controlled autoclave and method

Also Published As

Publication number Publication date
RS62796B1 (sr) 2022-02-28
WO2019049869A1 (fr) 2019-03-14
IL272652A (en) 2020-03-31
JP6557441B1 (ja) 2019-08-07
PT3680243T (pt) 2022-01-12
RU2754557C1 (ru) 2021-09-03
SI3680243T1 (sl) 2022-01-31
EP3680243A4 (fr) 2021-01-06
KR20200051585A (ko) 2020-05-13
HRP20220019T1 (hr) 2022-04-01
CN111051316A (zh) 2020-04-21
DK3680243T3 (da) 2022-01-10
TWI707859B (zh) 2020-10-21
CY1125355T1 (el) 2024-02-16
HUE056791T2 (hu) 2022-03-28
AU2018330578A1 (en) 2020-02-27
MX2020001786A (es) 2022-09-13
ZA202000970B (en) 2021-07-28
ES2903172T3 (es) 2022-03-31
MD3680243T2 (ro) 2022-05-31
EP3680243A1 (fr) 2020-07-15
IL272652B (en) 2022-09-01
SG11202001240XA (en) 2020-03-30
TW201920195A (zh) 2019-06-01
PH12020500341A1 (en) 2020-10-05
JOP20200030A1 (ar) 2020-02-12
US10239889B1 (en) 2019-03-26
MA50093B1 (fr) 2022-05-31
US20190071452A1 (en) 2019-03-07
AR112788A1 (es) 2019-12-11
CA3072740A1 (fr) 2019-03-14
AU2018330578B2 (en) 2022-11-10
LT3680243T (lt) 2021-11-25
UA125940C2 (uk) 2022-07-13
PL3680243T3 (pl) 2022-02-14
CO2020001471A2 (es) 2020-05-29
JPWO2019049869A1 (ja) 2019-11-07
BR112020003197A2 (pt) 2020-09-29
EP3680243B1 (fr) 2021-10-27
CN111051316B (zh) 2022-05-31
CL2020000376A1 (es) 2020-08-28
KR102307738B1 (ko) 2021-10-05

Similar Documents

Publication Publication Date Title
MA47433A (fr) Composé de quinazoline
DK3731771T3 (da) V462033dk00
MA45940A (fr) Composé hétérocyclique
DK3436444T3 (da) Heterocyklisk forbindelse
DK3519398T3 (da) Pyridinforbindelse
DE202018003363U8 (de) Handgelenkssphygmomanometer
CL2018000524S1 (es) Golilla
DK3351526T3 (da) Diisopentylterephthalat
DK3513569T3 (da) Øretelefon
DK3612519T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
MA50093A (fr) Composé pentacyclique
DK3568655T3 (da) Rekuperator
BR112016030730A2 (pt) Composto
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
MA43275A (fr) Composé de pyranodipyridine
DK3612237T3 (da) Genterapi
DK3597189T3 (da) Krystallinske forbindelser
DE112017003214A5 (de) Bohrwerkzeug
DK3568506T3 (da) Offeranode
DK3347403T3 (da) Polyalkoxyfedtforbindelse
DK3672941T3 (da) Pyridylpyridonforbindelser
DK3576686T3 (da) Brokbind
IT201600102119A1 (it) Seminatrice
DK3676276T3 (da) Spirothietannukleosider
DK3395159T3 (da) Ballepresse